PT2220214T - Método para aumentar a imunorreatividade - Google Patents

Método para aumentar a imunorreatividade

Info

Publication number: PT2220214T
Authority: PT; Portugal
Prior art keywords: increasing immune; resources; immune resources; increasing; immune
Prior art date: 2007-12-10

Application number

PT88604400T

Other languages

English (en)

Inventor

Schuster Manfred

Baier Gottfried

Loibner Hans

Lametschwandtner Günther

Wolf Dominik

Original Assignee

Medizinische Univ Innsbruck

Apeiron Biologics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-10

Filing date

2008-12-10

Publication date

2018-04-23

2008-12-10 Application filed by Medizinische Univ Innsbruck, Apeiron Biologics Ag filed Critical Medizinische Univ Innsbruck

2018-04-23 Publication of PT2220214T publication Critical patent/PT2220214T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Microbiology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PT88604400T 2007-12-10 2008-12-10 Método para aumentar a imunorreatividade PT2220214T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AT0199607A AT506041A1 (de)	2007-12-10	2007-12-10	Verfahren zur erhöhung der immunreaktivität

Publications (1)

Publication Number	Publication Date
PT2220214T true PT2220214T (pt)	2018-04-23

Family

ID=40585504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT88604400T PT2220214T (pt)	2007-12-10	2008-12-10	Método para aumentar a imunorreatividade

Country Status (25)

Country	Link
US (1)	US8809288B2 (pt)
EP (2)	EP2220214B1 (pt)
JP (2)	JP6118491B2 (pt)
KR (1)	KR101692797B1 (pt)
CN (2)	CN103898051B (pt)
AT (1)	AT506041A1 (pt)
AU (1)	AU2008336276C1 (pt)
BR (1)	BRPI0821003B8 (pt)
CA (1)	CA2708343C (pt)
CY (1)	CY1120136T1 (pt)
DK (1)	DK2220214T3 (pt)
EA (1)	EA018966B1 (pt)
ES (1)	ES2665928T3 (pt)
HR (1)	HRP20180558T1 (pt)
HU (1)	HUE037235T2 (pt)
IL (1)	IL206155A (pt)
LT (1)	LT2220214T (pt)
MX (1)	MX2010006296A (pt)
NZ (1)	NZ585646A (pt)
PL (1)	PL2220214T3 (pt)
PT (1)	PT2220214T (pt)
RS (1)	RS56941B1 (pt)
SI (1)	SI2220214T1 (pt)
WO (1)	WO2009073905A2 (pt)
ZA (1)	ZA201003791B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2566502T3 (es)	2006-09-13	2016-04-13	The Trustees Of Columbia University In The City Of New York	Agentes y métodos para provocar una respuesta inmune antitumoral
AT506041A1 (de) *	2007-12-10	2009-05-15	Univ Innsbruck	Verfahren zur erhöhung der immunreaktivität
EP2471548A1 (de)	2010-12-28	2012-07-04	Apeiron Biologics AG	siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
CN102552891A (zh) *	2011-12-27	2012-07-11	陆华	热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法
US9890215B2 (en) *	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
ES2897579T3 (es) *	2013-06-10	2022-03-01	Dana Farber Cancer Inst Inc	Métodos y composiciones para reducir la inmunosupresión por células tumorales
US10145908B2 (en)	2013-07-19	2018-12-04	Allegro Microsystems, Llc	Method and apparatus for magnetic sensor producing a changing magnetic field
EP3254701A1 (en)	2016-06-09	2017-12-13	IMBA-Institut für Molekulare Biotechnologie GmbH	Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
JP2020503043A (ja) *	2016-12-30	2020-01-30	セルラリティインコーポレイテッド	遺伝子改変されたナチュラルキラー細胞
US11766455B2 (en) *	2017-12-14	2023-09-26	Ezy Biotech Llc	Subject-specific tumor inhibiting cells and the use thereof
JP7600123B2 (ja)	2018-10-15	2024-12-16	ニューリックスセラピューティクス，インコーポレイテッド	ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
WO2020167518A1 (en)	2019-02-13	2020-08-20	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2020232691B2 (en)	2019-03-05	2023-06-29	Nkarta, Inc.	CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3953346A1 (en)	2019-04-09	2022-02-16	Nurix Therapeutics, Inc.	3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en)	2019-05-17	2022-03-23	Nurix Therapeutics, Inc.	Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
MX2021015675A (es)	2019-06-26	2022-02-03	Nurix Therapeutics Inc	Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
WO2021021761A1 (en) *	2019-07-30	2021-02-04	Nurix Therapeutics, Inc.	Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
EP4034141A1 (en)	2019-09-24	2022-08-03	Nurix Therapeutics, Inc.	Cbl inhibitors and compositions for expansion of immune cells
US11820781B2 (en)	2019-12-04	2023-11-21	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12016860B2 (en)	2021-04-08	2024-06-25	Nurix Therapeutics, Inc.	Combination therapies with Cbl-b inhibitor compounds
CN115554290B (zh) *	2021-07-01	2025-02-14	中国科学院分子细胞科学卓越创新中心	五羟色胺或其受体激动剂在治疗ilc2细胞介导的免疫性疾病中的应用
AU2022379494A1 (en)	2021-10-26	2024-05-30	Nurix Therapeutics, Inc.	Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
EP4289939A1 (en)	2022-06-10	2023-12-13	Apeiron Biologics AG	Population of transfected immune cells and method for their production
WO2025056732A1 (en)	2023-09-13	2025-03-20	Medizinische Universität Graz	Method for providing antigen-reactive lymphocytes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050037989A1 (en) *	2001-08-27	2005-02-17	Lewis David L.	Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
ATE494296T1 (de) *	2002-09-11	2011-01-15	Genentech Inc	Zusammensetzungen und verfahren für die tumordiagnose und behandlung
WO2004078130A2 (en)	2003-03-03	2004-09-16	Proteologics, Inc.	Posh interacting proteins and related methods
WO2004099388A2 (en) *	2003-03-05	2004-11-18	Proteologics, Inc.	Cbl-b polypeptides, complexes and related methods
DE602004025708D1 (de) *	2003-07-11	2010-04-08	Proteologics Inc	Ubiquitin-ligase-hemmer und verwandte verfahren
DE10347436B4 (de) *	2003-10-13	2007-08-02	Johann Wolfgang Goethe-Universität Frankfurt am Main	In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
WO2005044840A2 (en) *	2003-10-17	2005-05-19	The Cbr Institute For Biomedical Research, Inc.	Modulation of anergy and methods for isolating anergy-modulating compounds
WO2005069791A2 (en) *	2004-01-08	2005-08-04	Cedars-Sinai Medical Center	Compositions and methods for enhancing the th1 response in connection with dendritic cell vaccines
JP2008522951A (ja) *	2004-07-19	2008-07-03	ベイラー・カレツジ・オブ・メデイシン	サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
US7868159B2 (en)	2005-06-23	2011-01-11	Baylor College Of Medicine	Modulation of negative immune regulators and applications for immunotherapy
TWI368637B (en) *	2005-09-05	2012-07-21	Hon Hai Prec Ind Co Ltd	High lustrous nano paint and methods for manufacturing and using the same
US20070087988A1 (en)	2005-09-30	2007-04-19	New York University	Hematopoietic progenitor kinase 1 for modulation of an immune response
ES2566502T3 (es) *	2006-09-13	2016-04-13	The Trustees Of Columbia University In The City Of New York	Agentes y métodos para provocar una respuesta inmune antitumoral
AT506041A1 (de) *	2007-12-10	2009-05-15	Univ Innsbruck	Verfahren zur erhöhung der immunreaktivität

2007
- 2007-12-10 AT AT0199607A patent/AT506041A1/de not_active Application Discontinuation
2008
- 2008-12-10 PT PT88604400T patent/PT2220214T/pt unknown
- 2008-12-10 EP EP08860440.0A patent/EP2220214B1/de active Active
- 2008-12-10 NZ NZ585646A patent/NZ585646A/en unknown
- 2008-12-10 HR HRP20180558TT patent/HRP20180558T1/hr unknown
- 2008-12-10 LT LTEP08860440.0T patent/LT2220214T/lt unknown
- 2008-12-10 US US12/747,326 patent/US8809288B2/en active Active
- 2008-12-10 KR KR1020107013074A patent/KR101692797B1/ko active Active
- 2008-12-10 HU HUE08860440A patent/HUE037235T2/hu unknown
- 2008-12-10 SI SI200831934T patent/SI2220214T1/en unknown
- 2008-12-10 ES ES08860440.0T patent/ES2665928T3/es active Active
- 2008-12-10 CN CN201410151457.2A patent/CN103898051B/zh active Active
- 2008-12-10 RS RS20180255A patent/RS56941B1/sr unknown
- 2008-12-10 PL PL08860440T patent/PL2220214T3/pl unknown
- 2008-12-10 EA EA201000974A patent/EA018966B1/ru unknown
- 2008-12-10 DK DK08860440.0T patent/DK2220214T3/en active
- 2008-12-10 MX MX2010006296A patent/MX2010006296A/es active IP Right Grant
- 2008-12-10 AU AU2008336276A patent/AU2008336276C1/en active Active
- 2008-12-10 JP JP2010537207A patent/JP6118491B2/ja active Active
- 2008-12-10 CA CA2708343A patent/CA2708343C/en active Active
- 2008-12-10 BR BRPI0821003A patent/BRPI0821003B8/pt active IP Right Grant
- 2008-12-10 CN CN200880120180.XA patent/CN101918544B/zh active Active
- 2008-12-10 EP EP17203941.4A patent/EP3363892A1/de not_active Withdrawn
- 2008-12-10 WO PCT/AT2008/000443 patent/WO2009073905A2/de not_active Ceased
2010
- 2010-05-27 ZA ZA2010/03791A patent/ZA201003791B/en unknown
- 2010-06-03 IL IL206155A patent/IL206155A/en active IP Right Grant
2015
- 2015-06-18 JP JP2015123027A patent/JP6175103B2/ja active Active
2018
- 2018-04-17 CY CY20181100405T patent/CY1120136T1/el unknown

Also Published As

Publication number	Publication date
IL206155A0 (en)	2010-12-30
JP6118491B2 (ja)	2017-04-19
BRPI0821003A2 (pt)	2015-06-16
DK2220214T3 (en)	2018-04-16
JP2015231371A (ja)	2015-12-24
RS56941B1 (sr)	2018-05-31
SI2220214T1 (en)	2018-04-30
WO2009073905A3 (de)	2009-10-22
KR20100110779A (ko)	2010-10-13
KR101692797B1 (ko)	2017-01-05
EA018966B1 (ru)	2013-12-30
CN101918544B (zh)	2014-03-19
AT506041A1 (de)	2009-05-15
HUE037235T2 (hu)	2018-08-28
WO2009073905A2 (de)	2009-06-18
CA2708343A1 (en)	2009-06-18
EA201000974A1 (ru)	2010-12-30
CN103898051B (zh)	2019-07-26
CN101918544A (zh)	2010-12-15
JP6175103B2 (ja)	2017-08-02
NZ585646A (en)	2012-05-25
MX2010006296A (es)	2011-02-23
AU2008336276A1 (en)	2009-06-18
BRPI0821003B8 (pt)	2021-05-25
US20100260808A1 (en)	2010-10-14
CY1120136T1 (el)	2018-12-12
EP2220214B1 (de)	2018-01-17
CA2708343C (en)	2018-09-04
US8809288B2 (en)	2014-08-19
JP2011507806A (ja)	2011-03-10
EP3363892A1 (de)	2018-08-22
HRP20180558T1 (hr)	2018-06-01
EP2220214A2 (de)	2010-08-25
AU2008336276B2 (en)	2014-06-12
BRPI0821003B1 (pt)	2019-03-26
ZA201003791B (en)	2011-03-30
WO2009073905A8 (de)	2009-09-03
ES2665928T3 (es)	2018-04-30
IL206155A (en)	2014-07-31
PL2220214T3 (pl)	2018-07-31
AU2008336276C1 (en)	2015-01-15
CN103898051A (zh)	2014-07-02
LT2220214T (lt)	2018-03-26

Publication	Publication Date	Title
PT2220214T (pt)	2018-04-23	Método para aumentar a imunorreatividade
BRPI0906906A2 (pt)	2015-07-21	Método para preparar um composto e composto
IL251198B (en)	2019-05-30	Slip chip method
BRPI0814359A2 (pt)	2015-08-11	Método
BRPI0817226A2 (pt)	2015-06-16	Método
BRPI0817726A2 (pt)	2015-03-31	Método
BRPI0812164A2 (pt)	2014-12-16	Técnicas para provisão automática de software
BRPI1014262A2 (pt)	2017-05-23	anticorpos específicos para caderina-17
BR112014003798A2 (pt)	2017-03-01	método para fabricar um composto, e, composto
BRPI0917145A2 (pt)	2015-08-18	Método para fabricar biocombustíveis
BRPI0911885A2 (pt)	2015-12-22	processo para a redução de atrito
BRPI0813903A2 (pt)	2014-12-30	Processos para a prepração de pirazóis
BRPI0819568A2 (pt)	2017-07-04	métodos para a preparação de um composto
FI20075721L (fi)	2009-04-12	Menetelmä pyrolysoinnin toteuttamiseksi
BRPI0923266A2 (pt)	2016-01-26	metodo para recuperacao avancada de petroleo
FI20075465L (fi)	2008-12-19	Talteenottomenetelmä
BRPI0817394A2 (pt)	2015-03-31	Método para processamento de pozzolans
BRPI0812999A2 (pt)	2014-12-23	Método para preparar um composto
BRPI0812741A2 (pt)	2014-12-23	Método para separação de glóbulos
DK2210105T3 (da)	2013-11-04	Mycobakterium-antigener
BRPI1014267A2 (pt)	2016-04-12	processo para a carbonitrificação
BRPI0818674A2 (pt)	2014-10-14	Método para produção de anticorpos
BRPI0819448A2 (pt)	2015-05-05	Método para transações seguras
IL224921A0 (en)	2013-07-31	Method of transmitting traffic in a communications network and communications network apparatus
BRPI0813366A2 (pt)	2014-12-30	Método para executar uma combustão.